Drug Trial Radar · NCT04247542
ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection
Last checked: Nov 19, 2026Latest source record: Jan 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
53
Actual
Start
Mar 6, 2020
Primary completion
Oct 3, 2023
Study completion Nov 15, 2023
Sponsor
- Lead sponsor
- Acurx Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 30, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Segments 2A and 2B of this trial evaluate the safety, efficacy, pharmacokinetics, fecal concentrations, and fecal microbiome effects of ACX-362E \[ibezapolstat\] in patients with C. difficile infection (CDI).
Conditions
- Clostridium Difficile Infection
Interventions
IbezapolstatDrug
Investigational antibacterial agent
VancomycinDrug
Active comparator
Primary outcomes
What the sponsor says the trial is designed to measure.
- Segment 2A: Clinical Cure (CC) of Clostridioides Difficile Infection (CDI) Per Protocol (PP)/Modified Intent-to-Treat (mITT) PopulationTime frame: 12 days
- Segment 2B Per Protocol (PP) Population: Clinical Cure (CC) of Clostridioides Difficile Infection (CDI)Time frame: 12 days
- Segment 2B Intent-to-Treat (ITT) Population: Clinical Cure (CC) of Clostridioides Difficile Infection (CDI)Time frame: 12 days
Locations
29 sites in 1 country. Site status is shown where the registry gives one.
Acurx Site #118: Dr Janet Reiser
Scottsdale, Arizona
Acurx Site #115: Dr Neera Grover
Apple Valley, California
Acurx Site #125: Dr Karen Simon
Camarillo, California
Acurx Site #111: Dr Jatinder Pruthi
Lancaster, California
Acurx Site #131: Dr Michael Jardula
Palm Springs, California
Acurx Site #129: Dr Stuart Cohen
Sacramento, California
Acurx Site #105
Doral, Florida
Acurx Site #122: Dr Faride Ramos
Doral, Florida
Acurx Site #101: Dr Idalia Acosta
Miami, Florida
Acurx Site #124: Dr Yunior Silva-Barrero
Miami, Florida
Acurx Site #108: Dr Idania Garcia Del Sol
Miami, Florida
Acurx Site #116: Dr Erick Juarez
Miami, Florida
Acurx Site #119: Dr Jorge Paoli-Bruno
Miami, Florida
Acurx Site #107: Dr Belkis Delgado
Miami Springs, Florida
Acurx Site #117: Dr Rafael Companioni
Panama City, Florida
Acurx Site #102: Dr Richard Nathan
Idaho Falls, Idaho
Acurx Site #123: Dr Harry Schrager
Newton, Massachusetts
Acurx Site #104: Dr JeanMarie Houghton
Worcester, Massachusetts
Acurx Site #103: Dr John Pullman
Butte, Montana
Acurx Site #130: Dr Michael DiGiovanna
North Massapequa, New York
Acurx Site #127: Dr Christopher Connolley
Winston-Salem, North Carolina
Acurx Site #126: Dr Andrew Pearson
Myrtle Beach, South Carolina
Acurx Site #114: Dr Eugene Ryan
Chattanooga, Tennessee
Acurx Site #121: Dr Ramesh Gowrappala
Houston, Texas
Acurx Site #120: Dr Vanna Gold
Lampasas, Texas
Acurx Site #113: Dr Jennifer Vincent
Temple, Texas
Acurx Site #110: Dr Val Hansen
Bountiful, Utah
Acurx Site #106: Dr Bezawit Tekola
Fairfax, Virginia
Acurx Site #109: Dr Robert Brennan
Lynchburg, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.